ATE299369T1 - Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine - Google Patents

Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine

Info

Publication number
ATE299369T1
ATE299369T1 AT00953996T AT00953996T ATE299369T1 AT E299369 T1 ATE299369 T1 AT E299369T1 AT 00953996 T AT00953996 T AT 00953996T AT 00953996 T AT00953996 T AT 00953996T AT E299369 T1 ATE299369 T1 AT E299369T1
Authority
AT
Austria
Prior art keywords
cyclobenzaprine
compositions
treating
sleep disorders
low doses
Prior art date
Application number
AT00953996T
Other languages
English (en)
Inventor
Iredell W Iglehart Iii
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE299369T1 publication Critical patent/ATE299369T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT00953996T 1999-08-13 2000-08-11 Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine ATE299369T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14888199P 1999-08-13 1999-08-13
PCT/US2000/022082 WO2001012175A1 (en) 1999-08-13 2000-08-11 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine

Publications (1)

Publication Number Publication Date
ATE299369T1 true ATE299369T1 (de) 2005-07-15

Family

ID=22527835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00953996T ATE299369T1 (de) 1999-08-13 2000-08-11 Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine

Country Status (18)

Country Link
US (3) US6395788B1 (de)
EP (1) EP1202722B1 (de)
JP (1) JP2003506484A (de)
AR (1) AR025110A1 (de)
AT (1) ATE299369T1 (de)
AU (1) AU6635400A (de)
BR (1) BR0013017A (de)
CA (1) CA2380432A1 (de)
DE (1) DE60021266T2 (de)
ES (2) ES2192156B1 (de)
GB (1) GB2368522A (de)
HK (2) HK1047883A1 (de)
IL (1) IL147777A0 (de)
MX (1) MXPA02001569A (de)
NZ (1) NZ516749A (de)
PT (1) PT1202722E (de)
WO (1) WO2001012175A1 (de)
ZA (2) ZA200200619B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE434437T1 (de) * 1999-02-18 2009-07-15 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
JP4578083B2 (ja) * 2003-09-30 2010-11-10 小林製薬株式会社 催眠剤組成物
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
KR101068180B1 (ko) 2005-12-01 2011-09-28 오스펙스 파마슈티칼스, 인코포레이티드 세로토닌성 및/또는 노르에피네프린성 활성을 갖는 치환된펜에틸아민
EP1984066B1 (de) * 2006-02-16 2020-05-06 Imthera Medical, Inc. Auf rfid basierendes system zur therapeutischen behandlung eines patienten
US20100179215A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
ES2693948T3 (es) 2007-03-15 2018-12-14 Auspex Pharmaceuticals, Inc. Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
CA2697826A1 (en) 2007-10-09 2009-04-16 Imthera Medical, Inc. System and method for neural stimulation
US8629135B2 (en) * 2008-07-14 2014-01-14 Queen's University At Kingston Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer
EP2349139B1 (de) 2008-10-09 2017-05-31 Imthera Medical, Inc. Stimulierung eines hypoglossalen nervs zur steuerung der zungenposition bei einem patienten
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
CA2780096A1 (en) 2009-11-10 2011-05-19 Imthera Medical, Inc. System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue
LT2501234T (lt) 2009-11-20 2017-12-11 Tonix Pharma Holdings Limited Būdai ir kompozicijos, skirti simptomų, susijusių su potrauminiu streso sutrikimu, gydymui naudojant ciklobenzapriną
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) * 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
US9346742B2 (en) * 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
CN104684550A (zh) 2012-06-15 2015-06-03 通尼克斯制药有限公司 用于跨粘膜吸收的组合物和方法
PT2968992T (pt) 2013-03-15 2020-02-18 Tonix Pharma Holdings Ltd Formulações eutécticas de cloridrato de ciclobenzaprina e manitol
MX2017003644A (es) 2014-09-18 2017-10-31 Tonix Pharma Holdings Ltd Formulaciones eutecticas de clorhidrato de ciclobenzaprina.
CA3069699A1 (en) 2017-07-13 2019-01-17 Tonix Pharmaceuticals Holding Corp. Analogs of cyclobenzaprine and amitryptilene
US11826321B2 (en) 2017-12-11 2023-11-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
TW202019400A (zh) * 2018-08-20 2020-06-01 愛爾蘭商托尼克製藥控股有限公司 治療急性壓力症候群及創傷後壓力症候群之方法
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
JP2023521167A (ja) * 2020-04-08 2023-05-23 トニックス ファーマシューティカルズ ホールディング コーポレーション 性機能障害のシクロベンザプリン処置
JP2023554597A (ja) 2020-11-20 2023-12-28 トニックス ファーマシューティカルズ ホールディング コーポレイション アルコール使用障害のためのシクロベンザプリン処置
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1339636A (en) * 1917-02-23 1920-05-11 Tulloch Thomas Gregorie Fluid-tight joint for steam-pipes and the like
GB859187A (en) 1958-11-25 1961-01-18 United States Borax Chem Method for preparing substituted tris amino boranes
CA958643A (en) 1970-07-07 1974-12-03 Frosst (Charles E.) And Co. Pharmaceutical compositions containing cyclobenzaprine
FR2121529A1 (en) * 1971-01-05 1972-08-25 Merck & Co Inc Compsns contg cyclobenzaprine and indomethacin - chlordiazepoxide, phenylbutazone oxyphenbutazone or corticosteroid
US6358944B1 (en) * 1999-08-13 2002-03-19 Vela Pharmaceuticals, Inc. Methods and compositions for treating generalized anxiety disorder

Also Published As

Publication number Publication date
US20040029869A1 (en) 2004-02-12
GB2368522A (en) 2002-05-08
HK1047883A1 (zh) 2003-03-14
WO2001012175A8 (en) 2001-05-10
NZ516749A (en) 2004-03-26
PT1202722E (pt) 2005-11-30
GB0202908D0 (en) 2002-03-27
DE60021266D1 (de) 2005-08-18
MXPA02001569A (es) 2002-07-02
CA2380432A1 (en) 2001-02-22
AU6635400A (en) 2001-03-13
AR025110A1 (es) 2002-11-06
ES2245944T3 (es) 2006-02-01
DE60021266T2 (de) 2006-05-24
ES2192156B1 (es) 2005-02-16
HK1047691A1 (en) 2003-03-07
US20010046988A1 (en) 2001-11-29
JP2003506484A (ja) 2003-02-18
IL147777A0 (en) 2002-08-14
GB2368522A8 (en) 2002-06-13
BR0013017A (pt) 2002-04-16
HK1047691B (zh) 2006-05-12
ZA200200852B (en) 2003-07-30
ES2192156A1 (es) 2003-09-16
EP1202722A1 (de) 2002-05-08
ZA200200619B (en) 2003-04-23
US6395788B1 (en) 2002-05-28
WO2001012175A1 (en) 2001-02-22
US6541523B2 (en) 2003-04-01
EP1202722B1 (de) 2005-07-13

Similar Documents

Publication Publication Date Title
ATE299369T1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60109589D1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
ATE446097T1 (de) Verwendung von uridin in kombination mit cholin zur behandlung von gedächtnisstörungen
DE60027894D1 (de) Milchsäurebakterienkombination und deren verwendung zur behandlung und prävention von infektionen und entzündungen
DE60143360D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
DE122006000035I1 (de) D2-Agonist enthaltendes transdermales Therapeutisches System zur Behandlung des Parkinson-syndroms und Berfahren zu seiner Herstellung
DE69726245D1 (de) Befeuchtungsgerät zur Behandlung von Atemstillstand im Schlaf
DE59601624D1 (de) Verwendung von 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ATE237341T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von kreislaufstörungen, enthaltend l- carnitin derivate und ginkgo biloba extrakte
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
EE200300057A (et) Koostis vähi profülaktikaks ja raviks

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1202722

Country of ref document: EP

EEIH Change in the person of patent owner
EEIH Change in the person of patent owner